The drug maker Mylan is facing an investigation from the federal government.
The Department of Justice is determining if the company acted illegally when it classified its EpiPen as a generic drug and qualified for lower rebate payments to states.
The company's CEO has come under fire as the price of the emergency allergy shots skyrocketed in recent years.
Some senators are suggesting the company may have "gamed" the system to divert millions of dollars from taxpayers.
Download the ABC2 News app for the iPhone, Kindle and Android.
